Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Company codeILMN
Company nameIllumina Inc
IPO dateJun 28, 2000
Founded at2000
CEOMr. Jacob Thaysen, Ph.D.
Number of employees8970
Security typeOrdinary Share
Fiscal year-endJun 28
Address5200 Illumina Way
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92122
Phone18582024500
Websitehttps://www.illumina.com
Company codeILMN
IPO dateJun 28, 2000
Founded at2000
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data